Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025: III. Second workshop: 2. Participants

Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages)

Índice de contenido

Executive summary
I. Introduction
II. Background on the research project
	1. Research questions and objectives of the study
	2. Study approach and research tools
	3. Project past activities
III. Second workshop
	1. Aim and objectives
	2. Participants
	3. Method of work and proceedings
IV. Preliminary findings
	1. The methods: What has been learnt?
		1.1 Methods in context: How did the country teams use the methods?
		1.2 Methods in question: What were the main problems encountered and how to solve them?
		1.3 Relevance of the methods
	2. National drug policies: what has been learnt?
		2.1 Preliminary findings based on NDP indicators
		2.2 Preliminary interpretations based on NDP indicators
		2.3 Preliminary findings based on the political mapping
	3. Cross national analysis: What can be learnt at this stage?
		3.1 Relevance of the methods for cross national comparison
		3.2 Strengths and weaknesses of NDP from a cross national perspective
		3.3 Tentative explanations for cross national variations
	4. Broader capacity building
V. Conclusions of the workshop and follow-up plans
	1. Main outcomes
	2. Next steps
Annex 1: Research proposal
	I. Introduction
	II. The Problem
	III. Research Question and Objectives of Proposed Study
	IV. Study Approach
	V. Anticipated Outcomes
	VI. Methods
	VII. Time Line and Resources
	Selected References
Annex 2: List of participants
Annex 3: Agenda
Annex 4: Questionnaire on NDP performance assessment
Annex 5: Achievements of the national drug policies in the 12 countries
	Bulgaria
	Chad
	Colombia
	Guinea
	India
	Mali
	Philippines
	Sri Lanka
	Thailand
	Viet Nam
	Zambia
	Zimbabwe
Annex 6: Consolidated tables
Other documents in the DAP Research Series

2. Participants

The workshop included 26 participants (see List of Participants in Annex 2):

• Researchers from the initial group of countries: Colombia, Guinea, India, the Philippines, Sri Lanka, Viet Nam, Zambia, and Zimbabwe.

• Researchers from countries which joined the research later and implemented the WHO Indicators for Monitoring National Drug Policies and/or the political mapping: Bulgaria, Chad, Mali and Thailand.

• Resource persons to provide technical support in epidemiology and statistics.

• Coordinators from the Action Programme on Essential Drugs (WHO), the Harvard School of Public Health, and the Karolinska Institutet (IHCAR).

Table 2: Background information on the participating countries
	Bulgaria	Chad	Colombia	Guinea	India¹	Mali	Philippines	Sri Lanka	Thailand	Viet Nam	Zambia	Zimbabwe
Total population (in millions)	8.4	6.6	37.5	6.3	70.5	8.8	68	17.6	59	72.5	9.3	11.5
Life expectancy (years)	70.9	50.3	69	47	60.7F/57.3M	62F/59M²	65	75F/71M²	69.6	65	55F/50M²	61
GNP per capita (US$)	1186	169	1260	450	61	168	952	588	1650	220	350	438
Infant mortality rate (per 1,000)	16.3	145	27.3	136	60	103	56	17.2	25.95	46	123.3	61
Total public drug expenditure per capita (US$)	8.24	0.05	5.35	0.27	0.13	0.14	0.6	1.34	1.57³	0.46	na	4.49
Total value of international aid for drugs (cash + kind) (million US$)	0.2	5.2	0	na	0.02	4.8	na	0.5	na	7.2	na	9.25
Total value of local production (ex-factory price) sold in the country (million US$)	66.6	0.2	980	0	657.1	4.9	na	5.5	481.3	87	na	42.6
Total value of drug imports (CIF) (million US$)	29.44	11.6	20	na	na	11.7	171	50	187.3	152	na	44.7
Total number of pharmacies and outlets in the public sector (including health facilities and hospitals that dispense drugs)	1180	na	3250	399	1817	77	363	922	9648	22400	877	1037
Total number of pharmacies and drug outlets in the private sector⁴	2200	172	13000	199	14703	468	9985	1541	23842	19300	288	922

¹Figures for one state (Andhra Pradesh) only
²F = female / M = male
³Ministry of Public Health only
⁴In many countries, the number of drug outlets is far above the number of pharmacies

Source: Data coming from the country research 1993-1994-1995 (see Annex 6)